METTL3 inhibitor shows efficacy and synergy with venetoclax in preclinical models of AML

Dec. 29, 2023

Researchers from Epics Therapeutics SA presented preclinical data for EP-102, a novel small-molecule inhibitor of N6-adenosine-methyltransferase catalytic subunit (METTL3), being developed for the treatment of cancer.

BioWorld Science Conferences American Society of Hematology Cancer

Today's news in brief

BioWorld

BioWorld briefs for Jan. 30, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 30, 2024.

Corbus rockets on early clinical data for next-gen Nectin-4 ADC candidate

BioWorld

Shares of Corbus Pharmaceuticals Inc. (NASDAQ:CRBP) doubled on opening Jan. 26 and ended the day up a whopping 249% as investors got a look at data from a...

Following JPM, 2024 outlook ranges from hopeful to cautious

BioWorld

Setting the tone for the biopharma industry as it enters a new year, the J.P. Morgan Healthcare Conference (JPM) held each January has once again led to...

Tempest Therapeutics presents new TREX1 inhibitors for cancer

BioWorld Science

Tempest Therapeutics Inc. has divulged three-prime repair exonuclease 1 (TREX1) inhibitors reported to be useful for the treatment of cancer.